<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-165825</identifier>
<setSpec>1131-3587</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Edoxaban: Phase-III studies</dc:title>
<dc:description xml:lang="en">Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the HokusaiVTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients (AU)</dc:description>
<dc:creator>Lekuona Goya, Iñaki</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El edoxabán se ha estudiado extensamente en ensayos de fase III, tanto en fibrilación auricular no valvular (ensayo ENGAGE AF-TIMI 48) como en estudios de prevención de la tromboembolia venosa recurrente (estudio HOKUSAI-VTE) y de prevención tras cirugía ortopédica (estudio STARs). Asimismo, se han publicado recientemente distintos subanálisis de los ensayos fundamentales sobre los subtipos de accidente cerebrovascular y embolia periférica en pacientes tratados con amiodarona y pacientes de edad, que merecen ser analizados (AU)</dc:description>
<dc:source>Rev. esp. cardiol. Supl. (Ed. impresa);16(supl.A): 70a-77a, 2016. graf</dc:source>
<dc:identifier>ibc-165825</dc:identifier>
<dc:title xml:lang="es">Estudios en fase III del edoxabán</dc:title>
<dc:subject>^d1287^s22057</dc:subject>
<dc:subject>^d11622^s22054</dc:subject>
<dc:subject>^d14308^s22054</dc:subject>
<dc:subject>^d15261^s22079</dc:subject>
<dc:subject>^d651^s22079</dc:subject>
<dc:subject>^d55662^s22079</dc:subject>
<dc:subject>^d54857^s22083</dc:subject>
<dc:subject>^d30964</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d34247^s22054</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:type>article</dc:type>
<dc:date>201600</dc:date>
</metadata>
</record>
</ibecs-document>
